Du Hyun Song1, In Kuk Cho1, Dong Woo Shin2, Jong-Chan Lee1, Jai Young Cho3, Yoo-Seok Yoon3, Jin-Hyeok Hwang1, Ho-Seong Han3, Jaihwan Kim4. 1. Division of Gastroenterology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, Republic of Korea. 2. Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Republic of Korea. 3. Department of Surgery, Seoul National University Bundang Hosptial, Seoul National University College of Medicine, Seongnam, Korea. 4. Division of Gastroenterology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, Republic of Korea. drjaihwan@snu.ac.kr.
Abstract
PURPOSE: The C-reactive protein (CRP)/albumin ratio has been identified as a potential prognostic factor for several malignancies. We, therefore, assessed the prognostic role of the CRP/albumin ratio in resected extrahepatic cholangiocarcinoma (EC). MATERIALS AND METHODS: A total of 235 patients were retrospectively analyzed between March 2005 and December 2017. The correlations among the preoperative CRP/albumin ratio, clinicopathological factors, and clinical outcomes were investigated. RESULTS: There were 143 males (60.8%), and the median age at the diagnosis was 70.1 (range 41.0-85.5) years. Patients were diagnosed with perihilar bile duct cancer (n = 61) and distal bile duct cancer (n = 174). The median recurrence-free survival and overall survival were 32.7 and 38.7 months, respectively. The optimal prognostic cut-off point of the CRP/albumin ratio for the survival was 0.18 (× 103). According to the Kaplan-Meier analysis with a log-rank test, the high CRP/albumin ratio group (≥ 0.18) had a significantly shorter overall survival than the low CRP/albumin ratio group (< 0.18) (29.8 vs. 54.6 months, p = 0.002). A multivariate logistic regression analysis for the overall survival showed that CA19-9 ≥ 37 and a high CRP/albumin ratio were associated with a shorter overall survival. CONCLUSION: A high CRP/albumin ratio appears to be significantly associated with clinically worse outcomes in patients with resected EC.
PURPOSE: The C-reactive protein (CRP)/albumin ratio has been identified as a potential prognostic factor for several malignancies. We, therefore, assessed the prognostic role of the CRP/albumin ratio in resected extrahepatic cholangiocarcinoma (EC). MATERIALS AND METHODS: A total of 235 patients were retrospectively analyzed between March 2005 and December 2017. The correlations among the preoperative CRP/albumin ratio, clinicopathological factors, and clinical outcomes were investigated. RESULTS: There were 143 males (60.8%), and the median age at the diagnosis was 70.1 (range 41.0-85.5) years. Patients were diagnosed with perihilar bile duct cancer (n = 61) and distal bile duct cancer (n = 174). The median recurrence-free survival and overall survival were 32.7 and 38.7 months, respectively. The optimal prognostic cut-off point of the CRP/albumin ratio for the survival was 0.18 (× 103). According to the Kaplan-Meier analysis with a log-rank test, the high CRP/albumin ratio group (≥ 0.18) had a significantly shorter overall survival than the low CRP/albumin ratio group (< 0.18) (29.8 vs. 54.6 months, p = 0.002). A multivariate logistic regression analysis for the overall survival showed that CA19-9 ≥ 37 and a high CRP/albumin ratio were associated with a shorter overall survival. CONCLUSION: A high CRP/albumin ratio appears to be significantly associated with clinically worse outcomes in patients with resected EC.
Entities:
Keywords:
Albumin; C-reactive protein; Distal bile duct cancer; Extrahepatic cholangiocarcinoma; Perihilar bile duct cancer
Authors: Richard A Smith; Lorraine Bosonnet; Michael Raraty; Robert Sutton; John P Neoptolemos; Fiona Campbell; Paula Ghaneh Journal: Am J Surg Date: 2008-07-17 Impact factor: 2.565
Authors: Thomas Gerhardt; Sabine Milz; Michael Schepke; Georg Feldmann; Martin Wolff; Tilman Sauerbruch; Franz Ludwig Dumoulin Journal: World J Gastroenterol Date: 2006-09-14 Impact factor: 5.742
Authors: G Kasymjanova; N MacDonald; J S Agulnik; V Cohen; C Pepe; H Kreisman; R Sharma; D Small Journal: Curr Oncol Date: 2010-08 Impact factor: 3.677
Authors: M Stotz; A Gerger; F Eisner; J Szkandera; H Loibner; A L Ress; P Kornprat; W AlZoughbi; W A Zoughbi; F S Seggewies; C Lackner; T Stojakovic; H Samonigg; G Hoefler; M Pichler Journal: Br J Cancer Date: 2013-06-25 Impact factor: 9.075